METHODS: Outcomes (disease-free (DFS) and overall survival OS)) of 608 patients with HER2-non amplified eBC and treated with NAC were retrospectively analyzed according to CPS-EG score. We compared the prognostic stratification abilities of the CPS+EG in HER2-low and HER2-0 eBC, analyzing ER+ and ER- tumors separately.
RESULTS: In ER+ eBC, the CPS+EG scoring system seems to retain a prognostic value, both in HER2-low and HER2-0 tumors, by distinguishing populations with significantly different outcomes (good: score 0-1, poor: score 2-3, and very poor: score 4-5). Using C-indices for DFS and OS, CPS+EG provided the highest prognostic information in ER+ eBC, especially in HER2-0 tumors. In contrast, in ER- eBC, the CPS+EG does not appear to be able to distinguish different outcome groups, either in HER2-low or HER2-0 tumors. In ER- eBC, C-indices for DFS and OS were highest for pathological stage, reflecting the predominant prognostic importance of residual disease in this subtype.
CONCLUSIONS: HER2-low status does not influence the prognostic performance of the CPS+EG score. Our results confirm the usefulness of the CPS+EG score in stratifying the prognosis of ER+ eBC after NAC, for both HER2-0 and HER2-low tumors. For ER- eBC, HER2-low status does not influence the performance of the CPS+EG score, which was lower than that of the pathological stage alone.
方法:根据CPS-EG评分,回顾性分析608例HER2非扩增eBC患者的预后(无病(DFS)和总生存期OS)。我们比较了低HER2和HER2-0eBC中CPS+EG的预后分层能力,分别分析ER+和ER-肿瘤。
结果:在ER+eBC中,CPS+EG评分系统似乎保留了预后价值,在HER2低和HER2-0肿瘤中,通过区分具有显着不同结果的人群(好:得分0-1,差:得分2-3,非常差:得分4-5)。为DFS和OS使用C索引,CPS+EG在ER+eBC中提供了最高的预后信息,尤其是HER2-0肿瘤。相比之下,在ER-EBC中,CPS+EG似乎无法区分不同的结果组,无论是在HER2低或HER2-0肿瘤。在ER-eBC中,病理阶段的DFS和OS的C指数最高,反映了该亚型中残留疾病的主要预后重要性。
结论:HER2低状态不影响CPS+EG评分的预后表现。我们的结果证实了CPS+EG评分在NAC后对ER+eBC的预后进行分层的有用性,对于HER2-0和HER2低肿瘤。对于ER-eBC,低HER2状态不影响CPS+EG评分的表现,低于单独的病理阶段。